DOCSLIB.ORG

Metachronous Triple Genitourinary Tumors in a Single Patient Treated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metachronous Triple Genitourinary Tumors in a Single Patient Treated Korean J Urol Oncol 2014;12(2):86-88 Metachronous Triple Genitourinary Tumors in a Single Patient Treated by Partial Nephrectomy, Retropubic Radical Prostatectomy, and Transurethral Resection of Bladder Tumor Jang Hee Han1, Jong Kyou Kwon1, Joo Yong Lee1, Kang Su Cho2, Won Sik Ham1, Young Deuk Choi1 1Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, 2Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea A 75-year-old man was referred to our department for an incidentally detected right renal mass which was later treated by partial nephrectomy. Seven years later, a serum PSA level of 5.87ng/ml was detected and a digital rectal examination revealed a tiny, palpable nodule in the left lobe of prostate. The results of the prostate biopsy revealed prostate adenocarcinoma with a Gleason score of 7 (3＋4) in 5 of 12 cores. Retropubic radical prostatectomy was carried out. In follow-up imaging studies, positron emission tomography-computed tomography revealed a 1.3-cm papillary tumor located in the bladder and he underwent transurethral resection. To the best of our knowledge, this the first report of metachronous, triple primary, genitourinary malignant tumors in Korea. (Korean J Urol Oncol 2014;12:86-88) Key Words: Urogenital neoplasm; Neoplasms, Second primary Multiple primary cancers (MPC) in a single patient have be- niques have also attributed to the increase of this diagnosis. come a frequent finding in recent decades. However, MPC of To the best of our knowledge, there is little data reporting three or more sites is extremely rare reporting prevalence of the incidence and clinical features of this rare disease entity,4 0.029 to 1.7%.1-3 The etiologies of MPC appear to be complex and metachronous, triple primary, genitourinary malignant tu- and the main driving cause varies widely. Number of factors mors have not been reported in Korea so far. Herein, we pres- could interact with each other to cause this uncommon disease.4 ent a report of metachronous, triple primary, genitourinary ma- Furthermore, an aging society producing an increasing elderly lignant tumors occurring in the kidney, prostate, and bladder patient population, as well as advances in novel diagnostic tech- that were treated by an open partial nephrectomy (OPN), retro- pubic radical prostatectomy (RRP), and transurethral resection Received June 23, 2014, Revised August 7, 2014, of the bladder tumor(TURBT). Accepted August 11, 2014 Corresponding Author: Young Deuk Choi, Department of Urology CASE REPORT and Robot and Minimal Invasive Surgery Center, Severance Hospital, and Urological Science Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul On December 2005, a 75 year-old male patient was referred 120-752, Korea. Tel: 82-2-2228-2317, Fax: 82-2-312-2538, to Severance Hospital, Yonsei University Health System, Seoul, E-mail: [email protected] Korea, department of urology for an incidentally detected renal 86 Jang Hee Han, et al：Triple Genitourinary Metachronous Tumors 87 Fig. 1. (A) Computed tomography revealed an approximately 2-cm, well-enhanced, exophytic, mass enri- ching blood flow located in the anterior aspect of the midportion of the right kidney (arrow head). (B) Upon preoperative magnetic reso- nance image, PCa was suspected in both peripheral zones without defi- nite extraprostatic extention or seminal vesicle invasion. Fig. 2. (A) A 1.3-cm focal enhan- cing mass lesion was detected at the left ureterovesical junction of the urinary bladder in the PET-CT suggesting a bladder tumor (arrow- head). (B) Multiple bladder tumors up to 2cm were noted in the whole bladder wall during cystoscopy. mass. He had a smoking history of 90 pack-years and had no resonance images, prostate cancer(PCa) was suspected in both other remarkable past medical history. Ultrasonography and peripheral zones without a definite extraprostatic extention or computed tomography (CT) revealed an approximately 2cm, seminal vesicle invasion (Fig. 1B). Considering his age, per- well-enhanced, exophytic mass enriching blood flow located in formance status (ECOG 0), and Charlson Comorbidity Index the right kidney (Fig. 1A). He had undergone partial neph- (CCI), the patient underwent RRP for PCa. In the CCI, the his- rectomy with preservation of the ipsilateral adrenal gland. tory of RCC was excluded because RCC had been diagnosed Pathological evaluation revealed a 2.5x2.2cm mass consistent 5 years ago and his score was 0. The pathological diagnosis with renal cell carcinoma (RCC), conventional type, Fuhrman revealed prostate adenocarcinoma, with a Gleason score of 7 grade 1, without involvement of the resection margin or peri- (3＋4) and extracapsular extention without focal surgical mar- nephric fat (pT1aN0M0). There was no reported evidence of gin involvement or pelvic lymph node invasion (pT3aN0Mx). post-operative complications or recurrence during the routine Three months after surgery the PSA decreased to 0.1ng/ml follow-up periods. without adjuvant androgen deprivation therapy. On March 2012, he visited again presenting with lower uri- On May 2013, positron emission tomography-CT (PET-CT) nary tract symptoms (LUTS). As part of the routine evaluation was performed to evaluate recurrence or progression of the for LUTS, prostate-specific antigen (PSA) and transrectal ultra- prostate cancer which revealed 1.3-cm focal enhancing mass le- sonography (TRUS) were performed. Serum PSA level was sion at the left ureterovesical junction of the urinary bladder. 5.87ng/ml and prostate volume was 16ml. During the digital (Fig. 2A). Multiple bladder tumors up to 2cm were noted in rectal examination, a tiny nodule was palpable on the left lobe the whole bladder wall during cystoscopy (Fig. 2B), and metic- of the prostate gland. Finally, a TRUS-guided biopsy of the ulous TURBT was carried out. The pathological results re- prostate was performed for confirmative diagnosis. The patho- vealed urothelial carcinoma, low grade, pTaN0M0. After 6 cy- logical report indicated prostate adenocarcinoma with a Gleason cles of intravesical BCG instillation, routine postoperative fol- score of 7 (3＋4) in 5 of 12 cores. From preoperative magnetic low-up studies have shown no complications or recurrence for 88 대한비뇨기종양학술지：제12권 제2호 2014 RCC, PC, or bladder tumors thus far. tween RCC, PCa, and bladder tumors in metachronous MPC. Recently, genetic factors have been associated with urological DISCUSSION malignancies. SNORD43 is a reference gene suitable for ana- lyzing circulating micro-ribonucleic acids in patients with po- MPCs are a relatively well-known phenomenon. The etiology tential urological malignancies including PCa, urothelial carci- of multiple primary malignant tumors is rather complex and in- noma, and RCC.10 cludes environmental factors like tobacco, occupation, pollu- We firstly reported extremely rare case of metachronous tri- tion, ultraviolet light, genetic predisposition, previous medical ple genitourinary gumors in a single patient and suggested that treatment like radiation therapy or chemotherapy, gender-specif- the primary tumors are not as advanced initially when com- ic factors, hormonal factors, and finally interactions between pared to the synchronous type, the secondary tumor may be these factors.5 A few cases of genitourinary MPCs have been more advanced and more aggressive treatment should be con- reported throughout the world; however, none of them were sidered for such patients. metachronous MPCs which were detected more than 5 years later since the first cancer had developed. There also have been REFERENCES no reported case of metachronous, triple genitourinary MPC in 1. Hajdu SI, Hajdu EO. Multiple primary malignant tumors. Korea. Journal of the American Geriatrics Society 1968;16:16-26 In terms of the chronicity, we defined synchronous and meta- 2. Nemeth Z, Czigner J, Ivan L, Ujpal M, Barabas J, Szabo G. chronous cancer based on Moertel's definition.6 Synchronous Quadruple cancer, including triple cancers in the head and cancers are defined as those occurring within 6 months of the neck region. Neoplasma 2002;49:412-4 first primary cancer, while metachronous cancers were defined 3. Kim JH, Rha SY, Kim C, Kim GM, Yoon SH, Kim KH, et al. Clinicopathologic features of metachronous or synchronous more than 6 months later. It has been reported that the synchro- gastric cancer patients with three or more primary sites. Cancer nous MPC group had a greater number of advanced stage, ini- research and treatment : official journal of Korean Cancer tial primary malignancies and fewer advanced stage, subsequent Association 2010;42:217-24 primary malignancies, and that genitourinary MPCs were more 4. Arikan-Sengul C, Pehlivan Y, Sevinc A, Karakok M, Kalender frequent in the metachronous MPC group.7 The prostate was ME, Camci C. A case of metachronous triple primary urogen- ital cancer: urinary bladder, prostate, and renal cancer. the most frequent site of initial primary malignancy in the Onkologie 2009;32:122-4 metachronous MPC group, whereas the lung, bladder, and ure- 5. Beisland C, Talleraas O, Bakke A, Norstein J. Multiple pri- ter were the most common initial sites in the synchronous MPC mary malignancies in patients with renal cell carcinoma: a na- group. The most common malignancy pairing was PCa with ur- tional population-based cohort study. BJU Int 2006;97:698-702 othelial carcinoma involving the bladder and ureter (12%).7 6. Moertel CG. Multiple primary malignant neoplasms: historical perspectives. Cancer 1977;40:1786-92 Regarding risk factors for each cancer, bladder cancer is the 7. Powell S, Tarchand G, Rector T, Klein M. Synchronous and fourth most common malignancy in men and the tenth in metachronous malignancies: analysis of the Minneapolis women. Cigarette smoking is believed to contribute to ur- Veterans Affairs (VA) tumor registry. Cancer causes & con- othelial cancer, up to 50% in men and up to 40% in women. trol: CCC 2013;24:1565-73 Other implicated agents include aniline dyes, drugs, and ex- 8.
Load more

Recommended publications
  • Expression of the P53 Inhibitors MDM2 and MDM4 As Outcome
    ANTICANCER RESEARCH 36 : 5205-5214 (2016) doi:10.21873/anticanres.11091 Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer MAXIMILIAN CHRISTIAN KRIEGMAIR 1* , MA TT HIAS BALK 1, RALPH WIRTZ 2* , ANNETTE STEIDLER 1, CLEO-ARON WEIS 3, JOHANNES BREYER 4* , ARNDT HARTMANN 5* , CHRISTIAN BOLENZ 6* and PHILIPP ERBEN 1* 1Department of Urology, University Medical Centre Mannheim, Mannheim, Germany; 2Stratifyer Molecular Pathology, Köln, Germany; 3Institute of Pathology, University Medical Centre Mannheim, Mannheim, Germany; 4Department of Urology, University of Regensburg, Regensburg, Germany; 5Institute of Pathology, University Erlangen-Nuernberg, Erlangen, Germany; 6Department of Urology, University of Ulm, Ulm, Germany Abstract. Aim: To evaluate the prognostic role of the p53- Urothelical cell carcinoma (UCC) of the bladder is the second upstream inhibitors MDM2, MDM4 and its splice variant most common urogenital neoplasm worldwide (1). Whereas MDM4-S in patients undergoing radical cystectomy (RC) for non-muscle invasive UCC can be well treated and controlled muscle-invasive bladder cancer (MIBC). Materials and by endoscopic resection, for MIBC, which represents 30% of Methods: mRNA Expression levels of MDM2, MDM4 and tumor incidence, radical cystectomy (RC) remains the only MDM4-S were assessed by quantitative real-time polymerase curative option. However, MIBC progresses frequently to a chain reaction (qRT-PCR) in 75 RC samples. Logistic life-threatening metastatic disease with limited therapeutic regression analyses identified predictors of recurrence-free options (2). Standard clinical prognosis parameters in bladder (RFS) and cancer-specific survival (CSS). Results: High cancer such as stage, grade or patient’s age, have limitations expression was found in 42% (MDM2), 27% (MDMD4) and in assessing individual patient’s prognosis and response to 91% (MDM4-S) of tumor specimens.
    [Show full text]
  • Medsafe Sheet for Copaxone
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME COPAXONE® 20 mg/mL PRE-FILLED SYRINGE COPAXONE® 40 mg/mL PRE-FILLED SYRINGE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Copaxone 20 mg/mL contains 20 mg of glatiramer acetate. Copaxone 40 mg/mL contains 40 mg of glatiramer acetate. Glatiramer acetate, the active ingredient in both Copaxone 20 mg/mL and Copaxone 40 mg/mL, is the acetate salt of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine with an average molar fraction 0.141, 0.427, 0.095 and 0.338, respectively. The average molecular weight of glatiramer acetate is 5000 to 9000 Daltons. For a full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Copaxone is a clear, colourless solution for injection, in a pre-filled syringe. The pH of a 0.5% solution in water is in the range of 5.5 to 7.0 and an osmolarity of about 265 mOsmol/L and 300 mOsmol/L for the 20 mg/mL and 40 mg/mL, respectively. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Reduction of the frequency of relapses in patients with Relapsing Remitting Multiple Sclerosis. Treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent MRI lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded. 4.2 Dose and method of administration The only recommended route of administration of Copaxone injection is by the subcutaneous route. Copaxone should not be administered by the intravenous or intramuscular routes.
    [Show full text]
  • United States Patent (10) Patent No.: US 9,724,354 B2 Brake Et Al
    USOO9724354B2 (12) United States Patent (10) Patent No.: US 9,724,354 B2 Brake et al. (45) Date of Patent: Aug. 8, 2017 (54) COMBINATION OF CATALYTIC MTORC1/2 6,727.251 B2 4/2004 Bebbington et al. INHIBITORS AND SELECTIVE INHIBITORS g: R 1939: Shano et al. O OF AURORAAKNASE 7,049,116 B2 5, 2006 Shokat 7,148,228 B2 12/2006 Kasibhatla et al. (71) Applicant: Millennium Pharmaceuticals, Inc., 7,271,262 B2 9, 2007 tty al Cambridge, MA (US) 7,572,784 B2 8/2009 Claiborne et al. 8,026,246 B2 9, 2011 Claiborne et al. (72) Inventors: Rachael L. Brake, Natick, MA (US); 8,399.659 B2 3/2013 Claiborne et al. Huifeng Niu, Cambridge, MA (US) 9,102,678 B2 8, 2015 Claiborne et al. g Nu, 2C, 2001/0024.833 A1 9, 2001 Laborde et al. 2002fOO16976 A1 2/2002 Shokat (73) Assignee: Millennium Pharmaceuticals, Inc., 2002fO156081 A1 10, 2002 Hirst et al. Cambridge, MA (US) 2003/0022885 A1 1/2003 Bebbington et al. 2003/0055068 A1 3/2003 Bebbington et al. c - r 2003. O180924 A1 9, 2003 DeSimone (*) Notice: Sibi tO E. site th still 2003/0187001 A1 10, 2003 Calderwood et al. patent 1s extended or adjusted under 2005/0085472 A1 4/2005 Tanaka et al. U.S.C. 154(b) by 0 days. 2005. O197340 A1 9, 2005 Arora et al. 2006,0074074 A1 4/2006 Ohtsuka et al. (21) Appl. No.: 14/777,888 2006/0235031 A1 10, 2006 Arnold et al. 2006/0246551 A1 11/2006 Stack et al.
    [Show full text]
  • Human Anatomy As Related to Tumor Formation Book Four
    SEER Program Self Instructional Manual for Cancer Registrars Human Anatomy as Related to Tumor Formation Book Four Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISTRARS Book 4 - Human Anatomy as Related to Tumor Formation Second Edition Prepared by: SEER Program Cancer Statistics Branch National Cancer Institute Editor in Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch National Cancer Institute Assisted by Self-Instructional Manual Committee: Dr. Robert F. Ryan, Emeritus Professor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred A. Weiss Los Angeles, California Mary A. Kruse Bethesda, Maryland Jean Cicero, ART, CTR Health Data Systems Professional Services Riverdale, Maryland Pat Kenny Medical Illustrator for Division of Research Services National Institutes of Health CONTENTS BOOK 4: HUMAN ANATOMY AS RELATED TO TUMOR FORMATION Page Section A--Objectives and Content of Book 4 ............................... 1 Section B--Terms Used to Indicate Body Location and Position .................. 5 Section C--The Integumentary System ..................................... 19 Section D--The Lymphatic System ....................................... 51 Section E--The Cardiovascular System ..................................... 97 Section F--The Respiratory System ....................................... 129 Section G--The Digestive System ......................................... 163 Section
    [Show full text]
  • Information for Authors / Submission Process New
    INFORMATION FOR AUTHORS / SUBMISSION PROCESS NEW Electronic Submission Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for As of December 1, 2007, the Canadian Journal of Neurological Biomedical Publication International Committee of Sciences went to an Electronic Submission process. ALL manuscript submissions will be handled by an On-Line tracking system. Go to Medical Journal Editors www.cjns.org and click on SUBMIT YOUR MANUSCRIPT and For detailed instructions regarding style and layout refer to "Uniform follow the instructions. requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained on the website (we will no longer accept paper/disc submissions) http://www.icmje.org. Articles should be submitted under The manuscript submission process is broken into a series of five conventional headings of introduction, methods and materials, screens that gather detailed information about your manuscript and results, discussion, but other headings will be considered if more allow you to upload the pertinent files. The sequence of screens are as suitable. For Uniform Requirements for Sample References go to follows: http://www.nlm.nih.gov/bsd/uniform_requirements.html. After the manuscript is submitted, you will be asked to select the order you would like the files to be displayed in a merged PDF file 1. A long form asking for author information, title, abstract, and file that the system will create for you. Next, you will be directed to a quantities. page that will allow you to review your converted manuscript. If the 2. A screen asking for the actual file locations on your computer (via conversion is not correct, you can replace or delete your manuscript an open file dialog).
    [Show full text]
  • Antagonists of Il-6 to Prevent Or Treat
    (19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol.
    [Show full text]
  • Incidence of Urogenital Neoplasms in India
    Published online: 2021-06-17 Original Article Incidence of Urogenital Neoplasms in India Abstract Satyanarayana Objective: To study and compare the national and regional incidences and risk of developing Labani, of neoplasms of individual urogenital sites using 2012 – 2014 reports from the National Cancer Dishank Rawat, Registry Programme (NCRP) data. Materials and Methods: A number of incident cases, age- adjusted rates (AARs), and cumulative risk (0 – 64 years) pertaining to urogenital neoplasms, along Smita Asthana with the ICD-10 codes, were extracted. Data on indicators, namely number of incident cases, AARs Division of Epidemiology and one in a number of persons develop cancer were summarized for both the sexes in each of the and Biostatistics, Institute of Cytology and Preventive cancer registries and presented region-wise in the form of ranges. The proportion of all Results: Oncology, Indian Council of urogenital neoplasms in comparison to all cancers was 12.51% in women and 5.93% in men. Risk of Medical Research, Noida, development of urogenital cancers for women was maximum (1 in 50) in the North-eastern region, Uttar Pradesh, India followed by Rural West, South, and North. For men, the risk of developing neoplasms of urogenital sites was highest (1 in 250). For the neoplasms of the renal pelvis and ureter, both the incidence and risk were quite low for all genders across all the regions. Cervical neoplasms had the highest incidence (4.91 – 23.07) among female genital neoplasms, while prostate had the highest incidence (0.82 – 12.39) among male genital neoplasms. Conclusion: Making people aware of urogenital neoplasms and their risk factors are important for the public health awareness point of view.
    [Show full text]
  • Male Urogenital Cancers in Suriname 199
    Academic Journal of Suriname 2011, 2, 198-204 Biomedicine Full-length paper The incidence of malignancies of the male urogenital system in the Republic of Suriname from 1980 through 2004 Dennis R.A. Mans 1, Santosh S. Sardjoe 1, Martinus A. Vrede 2 1Department of Pharmacology, Faculty of Medical Sciences, Anton de Kom University of Suriname, Paramaribo, Suriname; 2Department of Pathology, Faculty of Medical Sciences, Anton de Kom University of Suriname, Paramaribo, Suriname Abstract The worldwide occurrence of male urogenital malignancies (cancers of prostate, penis, and testes, as well as those of kidneys and urinary bladder of men) varies from exceedingly rare to very common. In this study, incidence rates of these neoplasms in the Republic of Suriname between 1980 and 2004 have been assessed and compared with international data. Patient information was obtained from the Pathologic Anatomy Laboratory, population data from the General Bureau of Statistics. Sex-specific rates were calculated for cancer overall and for all anatomical sites, and stratified according to age groups 0 to 19, 20 to 49, and 50+ years, as well as the largest ethnic groups, viz. Hindustani, Creole, and Javanese. From these data, average yearly numbers and average rates per 100,000 men per year were calculated and expressed as means ± SDs. There were nearly 900 male urogenital malignancies in the period covered by this study, which corresponded to an overall rate of approximately 17. The most common urogenital neoplasm by far was prostatic cancer, occurring in more than three- quarters of cases and at a rate of about 13. Kidney, urinary bladder, penile, and testicular cancer were seen at rates lower than 2.
    [Show full text]
  • Risk Assessment Report Arsenic in Foods (Chemicals and Contaminants)
    [Tentative translation] Risk Assessment Report Arsenic in foods (Chemicals and Contaminants) Food Safety Commission Japan (FSCJ) October 2013 0 [Tentative translation] Contents Page Chronology of Discussions .................................................................................................... 3 List of members of the Food Safety Commission .................................................................. 3 List of members of the EPCC, the Food Safety Commission ................................................ 4 Executive summary ................................................................................................................ 6 I. Background ......................................................................................................................... 9 II. Outline of the Substances under Assessment .................................................................... 9 1. Physiochemical properties ......................................................................................... 9 (1) Metallic arsenic ................................................................................................... 9 (2) Inorganic arsenic compounds ........................................................................... 10 (3) Organic arsenic compounds .............................................................................. 12 (4) Analytical methods for arsenic ......................................................................... 16 2. Major use and production .......................................................................................
    [Show full text]
  • Profiling Analysis Reveals the Crucial Role of the Endogenous Peptides
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH ProfilingAnalysis Reveals the Crucial Role of the Endogenous Peptides in Bladder Cancer Progression This article was published in the following Dove Press journal: OncoTargets and Therapy Weijian Li,1,* Yang Background: Peptide drugs provide promising regimes in bladder cancer. In order to Zhang,1,2,* Youjian Li,1,3,* identify potential bioactive peptides involved in bladder cancer, we performed the present Yuepeng Cao,4 Jun Zhou,1 study. Zhongxu Sun,1 Wanke Wu,5 Methods: Liquid chromatography/mass spectrometry assay was used to compare the endo­ Xiaofang Tan,5 Yang Shao,5 genous peptides between bladder cancer and normal control. The potential biological func­ tions of these dysregulated peptides are assessed by GO analysis and KEGG pathway Kaipeng Xie,5,6 Xiang Yan1,2 analysis of their precursors. The SMART and UniProt databases are used to identify the 1 Department of Nephrology and Urology, The sequences of the dysregulated peptides located in the functional domains. The Open Targets Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center Platform database was used to investigate the precursors related to metabolic diseases. for Child Health, Hangzhou, People’s Republic Results: A total of 9 up-regulated peptides and 110 down-regulated peptides in bladder of China; 2Department of Urology, Drum Tower Hospital, Medical School of Nanjing cancer compared with normal control were identified (fold change > 1.2, P < 0.05). The MW University, Institute of Urology, Nanjing University, Nanjing, People’s Republic of China; of these dysregulated peptides ranged from 500 Da to 2500 Da and the MW of all identified 3Department of Urology Surgery, The People's peptides was below 3500 Da.
    [Show full text]
  • (51) International Patent Classification: (21) International Application Number: (84) Designated States (Unless Otherwise Indica
    ( (51) International Patent Classification: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Not classified SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (21) International Application Number: PCT/EP2020/053906 (84) Designated States (unless otherwise indicated, for every kind of regional protection available) . ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 14 February 2020 (14.02.2020) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, 19305197.6 18 February 2019 (18.02.2019) EP KM, ML, MR, NE, SN, TD, TG). (71) Applicants: INSERM (INSTITUT NATIONAL DE Published: LA SANTE ET DE LA RECHERCHE MEDICALE) — without international search report and to be republished [FR/FR]; 101, rue de Tolbiac, 75013 Paris (FR). upon receipt of that report (Rule 48. 2(g)) UNIVERSITE D'AIX MARSEILLE [FR/FR]; 58 Boule¬ — with sequence listing part of description (Rule 5.2(a)) vard Charles Livon, 13284 Marseille Cedex 07 (FR). CENTRE NATIONAL DE LA RECHERCHE SCIEN- TIFIQUE (CNRS) [FR/FR]; 3, Rue Michel Ange, 75016 Paris (FR).
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2010/0129357 Al Garcia-Martinez Et Al
    US 20100129357A1 US 20100129357A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2010/0129357 Al Garcia-Martinez et al. (43) Pub. Date: May 27,2010 (54) ANTIBODIES TO IL-6 AND USE THEREOF filed on Nov. 25, 2008, provisional application No. 61/117,811, filed on Nov. 25, 2008. (76) Inventors: Leon Garcia-Martinez, Woodinville, WA (US); Ann Elisabeth Carvalho Jensen, Publication Classification Edmonds, WA (US); Katie Olson, (51) Int. Cl. Kenmore, WA (US); Ben Dutzar, A61K 39/395 (2006.01) Seattle, WA (US); Ethan Ojala, A61P 37/02 (2006.01) Snohomish, WA (US); Brian Kovacevich, Snohomish, WA (US); (52) U.S. Cl.......................................................... 424/133.1 John Latham, Seattle, WA (US); Jeffrey T. L. Smith, Redmond, WA (US) (57) ABSTRACT Correspondence Address: The present invention is directed to therapeutic methods HUNTON & WILLIAMS LLP using IL-6 antagonists such as an Abl antibody or antibody INTELLECTUAL PROPERTY DEPARTMENT fragment having binding specificity for IL-6 to prevent or 1900 K STREET, N.W., SUITE 1200 treat disease or to improve survivability or quality of life of a WASHINGTON, DC 20006-1109 (US) patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of develop­ (21) Appl. No.: 12/502,581 ing) an elevated serum C-reactive protein level, reduced (22) Filed: Jul. 14, 2009 serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or Related U.S. Application Data fatigue prior to treatment. The subject therapies also may (60) Provisional application No. 61/117,861, filed on Nov.
    [Show full text]